Cargando…
BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial
BACKGROUND: Pruritus (itch) is a symptom commonly experienced by patients with cholestatic liver diseases such as primary biliary cholangitis (PBC, previously referred to as primary biliary cirrhosis). Bile acids (BAs) have been proposed as potential pruritogens in PBC. The ileal bile acid transport...
Autores principales: | Hegade, Vinod S., Kendrick, Stuart F. W., Dobbins, Robert L., Miller, Sam R., Richards, Duncan, Storey, James, Dukes, George, Gilchrist, Kim, Vallow, Susan, Alexander, Graeme J., Corrigan, Margaret, Hirschfield, Gideon M., Jones, David E. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950723/ https://www.ncbi.nlm.nih.gov/pubmed/27431238 http://dx.doi.org/10.1186/s12876-016-0481-9 |
Ejemplares similares
-
Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis
por: Al-Dury, Samer, et al.
Publicado: (2018) -
Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
por: Al-Dury, Samer, et al.
Publicado: (2018) -
Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise
por: Corrigan, Margaret, et al.
Publicado: (2019) -
Do the Effects of Resveratrol on Thermogenic and Oxidative Capacities in IBAT and Skeletal Muscle Depend on Feeding Conditions?
por: Milton-Laskibar, Iñaki, et al.
Publicado: (2018) -
Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study
por: Loomes, Kathleen M., et al.
Publicado: (2022)